Profile data is unavailable for this security.
About the company
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.
- Revenue in USD (TTM)165.85m
- Net income in USD-79.66m
- Incorporated1997
- Employees593.00
- LocationGyre Therapeutics Inc12770 High Bluff Drive, Suite 150SAN DIEGO 92130United StatesUSA
- Phone+1 (619) 949-3681
- Fax+1 (302) 636-5454
- Websitehttps://www.gyretx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics Inc | 138.71m | -195.54m | 1.27bn | 296.00 | -- | 8.08 | -- | 9.13 | -1.79 | -1.79 | 1.23 | 1.34 | 0.3799 | 1.04 | 3.49 | 468,608.10 | -53.55 | -65.64 | -75.79 | -71.72 | 89.57 | -- | -140.97 | -1,513.03 | 2.38 | -6.19 | 0.5664 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| CareDx Inc | 312.78m | -143.56m | 1.27bn | 635.00 | -- | 4.60 | -- | 4.06 | -2.70 | -2.70 | 5.95 | 5.15 | 0.6395 | 5.75 | 5.29 | 492,559.10 | -29.35 | -17.54 | -34.84 | -20.85 | 65.77 | 65.50 | -45.90 | -27.78 | 3.87 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
| Maravai Lifesciences Holdings Inc | 278.59m | -132.08m | 1.28bn | 580.00 | -- | 2.93 | -- | 4.60 | -0.998 | -0.998 | 2.09 | 1.73 | 0.1501 | 3.07 | 6.36 | 428,592.30 | -8.74 | 12.67 | -11.38 | 15.46 | 46.73 | 74.79 | -58.24 | 37.32 | 9.28 | -1.59 | 0.4167 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Cassava Sciences Inc | 0.00 | -15.37m | 1.29bn | 29.00 | -- | 6.84 | -- | -- | -0.4054 | -0.4054 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -6.97 | -30.74 | -8.35 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Vir Biotechnology Inc | 78.62m | -533.34m | 1.32bn | 587.00 | -- | 1.06 | -- | 16.82 | -3.92 | -3.92 | 0.5794 | 9.08 | 0.0444 | -- | -- | 133,931.90 | -30.10 | -0.6081 | -32.71 | -0.7192 | 98.78 | -- | -678.40 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Upstream Bio Inc | 2.22m | -54.81m | 1.34bn | 38.00 | -- | -- | -- | 605.19 | -1.07 | -1.07 | 0.0433 | 4.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,823.82 | -- | -- | -- | 0.00 | -- | 96.37 | -- | -60.28 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -82.83m | 1.37bn | 52.00 | -- | 4.48 | -- | -- | -1.93 | -1.93 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -26.91 | -42.26 | -28.35 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Kura Oncology Inc | 0.00 | -197.55m | 1.37bn | 142.00 | -- | 3.24 | -- | -- | -2.36 | -2.36 | 0.00 | 5.45 | 0.00 | -- | -- | 0.00 | -41.48 | -26.04 | -44.66 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0219 | -- | -- | -- | -12.36 | -- | -- | -- |
| Novavax Inc | 987.67m | -294.33m | 1.43bn | 1.54k | -- | -- | -- | 1.44 | -2.76 | -2.76 | 7.41 | -2.70 | 0.5638 | 21.98 | 4.63 | 640,095.30 | -16.80 | -46.06 | -78.53 | -269.57 | 63.67 | -- | -29.80 | -75.94 | 1.03 | -18.79 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Gyre Therapeutics Inc | 165.85m | -79.66m | 1.43bn | 593.00 | -- | 21.71 | -- | 8.63 | -0.8638 | -0.8638 | 1.43 | 0.7056 | 2.49 | -- | 17.81 | 279,674.50 | -103.20 | -73.59 | -167.87 | -99.94 | 96.15 | -- | -41.48 | -205.62 | 3.07 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Praxis Precision Medicines Inc | 1.61m | -151.02m | 1.45bn | 82.00 | -- | 3.62 | -- | 904.31 | -10.29 | -10.29 | 0.1058 | 21.52 | 0.0061 | -- | -- | 19,573.17 | -57.75 | -74.04 | -63.81 | -85.12 | -- | -- | -9,409.22 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Travere Therapeutics Inc | 203.45m | -348.96m | 1.55bn | 380.00 | -- | -- | -- | 7.62 | -4.52 | -4.56 | 2.63 | -0.3909 | 0.3043 | 0.7192 | 10.24 | 535,386.80 | -52.19 | -36.95 | -69.25 | -44.77 | 95.21 | 95.92 | -171.52 | -165.79 | 1.68 | -- | 1.09 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -258.08m | 1.59bn | 268.00 | -- | 4.82 | -- | -- | -2.75 | -2.75 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -52.01 | -35.26 | -56.17 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0605 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| BioCryst Pharmaceuticals Inc | 412.58m | -123.82m | 1.61bn | 536.00 | -- | -- | -- | 3.91 | -0.6073 | -0.6073 | 2.01 | -2.26 | 0.8136 | 0.4297 | 6.54 | 769,736.90 | -24.42 | -47.95 | -32.17 | -64.89 | 98.06 | 97.06 | -30.01 | -114.94 | 2.73 | -0.488 | 2.29 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
Data as of Nov 08 2024. Currency figures normalised to Gyre Therapeutics Inc's reporting currency: US Dollar USD
1.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 463.73k | 0.50% |
| Geode Capital Management LLCas of 30 Jun 2024 | 259.81k | 0.28% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 222.39k | 0.24% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 96.08k | 0.10% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 32.70k | 0.04% |
| Charles Schwab Investment Management, Inc.as of 30 Jun 2024 | 23.09k | 0.03% |
| BlackRock Investment Management LLCas of 30 Jun 2024 | 18.91k | 0.02% |
| Winton Capital Management Ltd.as of 30 Jun 2024 | 18.47k | 0.02% |
| BlackRock Advisors LLCas of 30 Jun 2024 | 14.88k | 0.02% |
| The Bank of New York Mellon Corp. (Investment Management)as of 30 Jun 2024 | 14.19k | 0.02% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
